The Mind Your Meds awareness campaign, targeted at patients and caregivers, shares insights on medication adherence and the pharmacy support systems available to help.
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the United States, subject to regulatory approval, no later than Feb. 21, 2025.